country,publication_number,kind,title,applicants,inventors,abstract,publication_date,priority_date,relevance_score,ai_summary,link,date_added,is_new
EP,4132584,A1,MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS,"UNIV CALIFORNIA [US], THE REGENTS OF THE UNIVERSITY OF CALIFORNIA","CAMPAGNA JESUS [US], JOHN VARGHESE [US], CAMPAGNA, Jesus,",,20230215,20200407,0.7765243053436279,MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS,https://worldwide.espacenet.com/patent/search?q=pn%3DEP4132584,02/12/2025,NO
WO,2023091904,A1,A NOVEL WAY FOR BRAIN-SPECIFIC DELIVERY OF MOLECULES FOR THE TREATMENT OF BRAIN DISEASES,"WEST VIRGINIA UNIV BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIV [US], WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY","SARKAR SAUMYENDRA [US], SIMPKINS JAMES [US], SARKAR, Saumyendra,","A composition comprising a brain targeted exosome derived from mesenchymal stem cells for systemically delivering an agent to target cells or tissues in the central nervous system of a patient, wherein the exosome expresses blood brain barrier (BBB) crossing central nervous system (CNS) specific AAV synthetic capsid (CAP) peptide. A method is provided for genetically engineering exosomes comprising joining a selected functional AAV capsid domain specific peptide (CAP), and fusing said CAP to lysosome-associated membrane glycoprotein (Lanp2b) to form a CAP-Lam2b fusion protein, and expressing CAP-lamp2b fusion protein on the surface of a mesenchymal stem cell derived exosome.",20230525,20211116,0.7635971307754517,"A composition comprising a brain targeted exosome derived from mesenchymal stem cells for systemically delivering an agent to target cells or tissues in the central nervous system of a patient, wherein the exosome expresses blood brain barrier (BBB) crossing central nervous system (CNS) specific AAV synthetic capsid (CAP) peptide. A method is provided for genetically engineering exosomes comprising joining a selected functional AAV capsid domain specific peptide (CAP), and fusing said CAP to lys",https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023091904,02/12/2025,NO
US,2025032550,A1,A NOVEL WAY FOR BRAIN-SPECIFIC DELIVERY OF MOLECULES FOR THE TREATMENT OF BRAIN DISEASES,"WEST VIRGINIA UNIV BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIV [US], West Virginia University Board of Governors on behalf of West Virginia University","SARKAR SAUMYENDRA [US], SIMPKINS JAMES W [US], SARKAR, Saumyendra,","A composition comprising a brain targeted exosome derived from mesenchymal stem cells for systemically delivering an agent to target cells or tissues in the central nervous system of a patient, wherein the exosome expresses blood brain barrier (BBB) crossing central nervous system (CNS) specific AAV synthetic capsid (CAP) peptide. A method is provided for genetically engineering exosomes comprising joining a selected functional AAV capsid domain specific peptide (CAP), and fusing said CAP to lysosome-associated membrane glycoprotein (Lanp2b) to form a CAP-Lam2b fusion protein, and expressing CAP-lamp2b fusion protein on the surface of a mesenchymal stem cell derived exosome.",20250130,20211116,0.7635971307754517,"A composition comprising a brain targeted exosome derived from mesenchymal stem cells for systemically delivering an agent to target cells or tissues in the central nervous system of a patient, wherein the exosome expresses blood brain barrier (BBB) crossing central nervous system (CNS) specific AAV synthetic capsid (CAP) peptide. A method is provided for genetically engineering exosomes comprising joining a selected functional AAV capsid domain specific peptide (CAP), and fusing said CAP to lys",https://patents.google.com/patent/US2025032550,02/12/2025,NO
EP,4401782,A1,SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS,"THE REGENTS OF UNIV OF CALIFORNIA [US], The Regents of University of California","JOHN VARGHESE [US], CAMPAGNA JESUS [US], JOHN, Varghese,",,20240724,20210914,0.7174035310745239,SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS,https://worldwide.espacenet.com/patent/search?q=pn%3DEP4401782,02/12/2025,NO
US,2023285291,A1,MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS,"UNIV CALIFORNIA [US], The Regents of the University of California","CAMPAGNA JESUS [US], JOHN VARGHESE [US], Campagna, Jesus,","This invention provides improved synthetic exosomes for delivery a one or more therapeutic agents to the central nervous system. In certain embodiments the synthetic exosome comprises a liposome formed from a lipid bilayer, where said lipid bilayer comprises: one or more phospholipids selected from the group consisting of phosphate lipids, phosphoglycerol lipids, phosphocholine lipids, and phosphoethanolamine lipids where the lipid carbon chain ranges from 3 to 24 carbon atoms; cholesterol, a cholesterol derivative (e.g., cholesterol hemicsuccinate), or a phytosterol; and a non-ionic surfactant; wherein the lipid bilayer does not contain an alcohol; and the liposome ranges in size from about 50 nm up to about 200 nm in diameter. Typically, the synthetic exosome is capable of crossing the blood brain barrier without substantially leaking said therapeutic moiety.",20230914,20200407,0.6720284223556519,"This invention provides improved synthetic exosomes for delivery a one or more therapeutic agents to the central nervous system. In certain embodiments the synthetic exosome comprises a liposome formed from a lipid bilayer, where said lipid bilayer comprises: one or more phospholipids selected from the group consisting of phosphate lipids, phosphoglycerol lipids, phosphocholine lipids, and phosphoethanolamine lipids where the lipid carbon chain ranges from 3 to 24 carbon atoms; cholesterol, a ch",https://patents.google.com/patent/US2023285291,02/12/2025,NO
WO,2023043700,A1,SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS,"UNIV CALIFORNIA [US], THE REGENTS OF THE UNIVERSITY OF CALIFORNIA","JOHN VARGHESE [US], CAMPAGNA JESUS [US], JOHN, Varghese,","This invention provides synthetic exosomes that contain and deliver an effective amount of a gene editor. In certain embodiments the synthetic exosome comprises a liposome formed from a lipid bilayer, where said lipid bilayer comprises: one or more phospholipids selected from the group consisting of phosphate lipids, phosphoglycerol lipids, phosphocholine lipids, and phosphoethanolamine lipids where the lipid carbon chain ranges from 3 to 24 carbon atoms; cholesterol, a cholesterol derivative, or a phytosterol; and a non- ionic surfactant; where the lipid bilayer does not contain an alcohol; the exosome is less than about 200 nm in diameter; and the exosome contains a guide RNA (gRNA) and a cytidine base editor, where the gRNA comprise a sequence that directs said n-Cas9-cytidine deaminase to edit the codon for amino acid 112 of the gene encoding ApoE4.",20230323,20210914,0.6343739032745361,"This invention provides synthetic exosomes that contain and deliver an effective amount of a gene editor. In certain embodiments the synthetic exosome comprises a liposome formed from a lipid bilayer, where said lipid bilayer comprises: one or more phospholipids selected from the group consisting of phosphate lipids, phosphoglycerol lipids, phosphocholine lipids, and phosphoethanolamine lipids where the lipid carbon chain ranges from 3 to 24 carbon atoms; cholesterol, a cholesterol derivative, o",https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023043700,02/12/2025,NO
US,2024252678,A1,SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS,"UNIV CALIFORNIA [US], The Regents of the University of California","JOHN VARGHESE [US], CAMPAGNA JESUS [US], John, Varghese,","This invention provides synthetic exosomes that contain and deliver an effective amount of a gene editor. In certain embodiments the synthetic exosome comprises a liposome formed from a lipid bilayer, where said lipid bilayer comprises: one or more phospholipids selected from the group consisting of phosphate lipids, phosphoglycerol lipids, phosphocholine lipids, and phosphoethanolamine lipids where the lipid carbon chain ranges from 3 to 24 carbon atoms: cholesterol, a cholesterol derivative, or a phytosterol; and a non-ionic surfactant; where the lipid bilayer does not contain an alcohol: the exosome is less than about 200 nm in diameter; and the exosome contains a guide RNA (gRNA) and a cytidine base editor, where the gRNA comprise a sequence that directs said n-Cas9-cytidine deaminase to edit the codon for amino acid 112 of the gene encoding ApoE4.",20240801,20210914,0.6325002312660217,"This invention provides synthetic exosomes that contain and deliver an effective amount of a gene editor. In certain embodiments the synthetic exosome comprises a liposome formed from a lipid bilayer, where said lipid bilayer comprises: one or more phospholipids selected from the group consisting of phosphate lipids, phosphoglycerol lipids, phosphocholine lipids, and phosphoethanolamine lipids where the lipid carbon chain ranges from 3 to 24 carbon atoms: cholesterol, a cholesterol derivative, o",https://patents.google.com/patent/US2024252678,02/12/2025,NO
US,2023114434,A1,EXTRACELLULAR VESICLES FOR TREATING NEUROLOGICAL DISORDERS,"CODIAK BIOSCIENCES INC [US], Codiak BioSciences, Inc","VERMA AJAY [US], SOOS TIM [US], ROSS NIKKI [US]","The present disclosure relates to extracellular vesicles (EVs) that are capable of targeting a cell in the CNS of a subject. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders of the CNS (e.g., neurological disorders).",20230413,20200313,0.6322937607765198,The present disclosure relates to extracellular vesicles (EVs) that are capable of targeting a cell in the CNS of a subject. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders of the CNS (e.g,https://patents.google.com/patent/US2023114434,02/12/2025,NO
WO,2024025809,A1,CNS DELIVERY,"CARMINE THERAPEUTICS PTE LTD [SG], NAT UNIV SINGAPORE [SG], LE MINH THI NGUYET","LE MINH THI NGUYET [SG], LAM BRENDA WAN SHING [SG], HAUT JR [SG]","The present disclosure describes delivery of nucleic acids to the central nervous system using extracellular vesicles, and in particular red blood cell extracellular vesicles.",20240201,20220723,0.6180355548858643,"The present disclosure describes delivery of nucleic acids to the central nervous system using extracellular vesicles, and in particular red blood cell extracellular vesicles.",https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024025809,02/12/2025,NO
AU,2021238317,A1,Designer extracellular vesicles for treating excitotoxicity,"OHIO STATE INNOVATION FOUNDATION [US], OHIO STATE INNOVATION FOUNDATION","HIGUITA-CASTRO NATALIA, GALLEGO-PEREZ DANIEL, HIGUITA-CASTRO, Natalia,","Disclosed herein are designer extracellular vesicles (EVs) functionalized with glutamate receptors (e.g., mGluR4 and mGluR8), which can selectively target injured regions of the CNS experiencing excitotoxicity. mGluR4 and mGluR8-decorated EVs preferentially anchor into injured areas of the CNS with a marked increase in extracellular glutamate associated with profuse neuro- and excitotoxicity. Therefore, glutamate receptor decoration can lead to enhanced homing in glutamate-rich areas of the CNS.",20220929,20200317,0.597074031829834,"Disclosed herein are designer extracellular vesicles (EVs) functionalized with glutamate receptors (e.g., mGluR4 and mGluR8), which can selectively target injured regions of the CNS experiencing excitotoxicity",https://worldwide.espacenet.com/patent/search?q=pn%3DAU2021238317,02/12/2025,NO
US,2023226118,A1,DESIGNER EXTRACELLULAR VESICLES FOR TREATING EXCITOTOXICITY,"OHIO STATE INNOVATION FOUNDATION [US], OHIO STATE INNOVATION FOUNDATION","HIGUITA-CASTRO NATALIA [US], GALLEGO-PEREZ DANIEL [US], HIGUITA-CASTRO, Natalia,","Disclosed herein are designer extracellular vesicles (EVs) functionalized with glutamate receptors (e.g., mGluR4 and mGluR8), which can selectively target injured regions of the CNS experiencing excitotoxicity. mGluR4 and mGluR8-decorated EVs preferentially anchor into injured areas of the CNS with a marked increase in extracellular glutamate associated with profuse neuroand excitotoxicity. Therefore, glutamate receptor decoration can lead to enhanced homing in glutamate-rich areas of the CNS.",20230720,20200317,0.5949035286903381,"Disclosed herein are designer extracellular vesicles (EVs) functionalized with glutamate receptors (e.g., mGluR4 and mGluR8), which can selectively target injured regions of the CNS experiencing excitotoxicity",https://patents.google.com/patent/US2023226118,02/12/2025,NO
MX,2022011409,A,DESIGNER EXTRACELLULAR VESICLES FOR TREATING EXCITOTOXICITY.,"OHIO STATE INNOVATION FOUNDATION [US], OHIO STATE INNOVATION FOUNDATION","GALLEGO-PEREZ DANIEL [US], HIGUITA-CASTRO NATALIA, GALLEGO-PEREZ Daniel,","Disclosed herein are designer extracellular vesicles (EVs) functionalized with glutamate receptors (e.g., mGluR4 and mGluR8), which can selectively target injured regions of the CNS experiencing excitotoxicity. mGluR4 and mGluR8-decorated EVs preferentially anchor into injured areas of the CNS with a marked increase in extracellular glutamate associated with profuse neuro- and excitotoxicity. Therefore, glutamate receptor decoration can lead to enhanced homing in glutamate-rich areas of the CNS.",20221202,20200317,0.5814989805221558,"Disclosed herein are designer extracellular vesicles (EVs) functionalized with glutamate receptors (e.g., mGluR4 and mGluR8), which can selectively target injured regions of the CNS experiencing excitotoxicity",https://worldwide.espacenet.com/patent/search?q=pn%3DMX2022011409,02/12/2025,NO
CN,115666655,A,Designer extracellular vesicles for treatment of excitatory toxicity,"OHIO STATE INNOVATION FOUNDATION, 俄亥俄州立创新基金会","HIQUITA CASTRO NATHALIE, GALLEGO PEREZ DANIEL, N·伊基塔卡斯特罗,","Disclosed herein are designer extracellular vesicles (EVs) functionalized with glutamate receptors (e.g., mGluR4 and mGluR8), which can selectively target CNS impaired regions that undergo excitatory toxicity. The mGluR4 and mGluR8 decorated EVs are preferably anchored into damaged areas in the CNS where the significant increase in extracellular glutamic acid is associated with substantial neurotoxicity and excitatory toxicity. Thus, glutamate receptor decoration may result in enhanced homing of glutamic acid rich regions in the CNS.",20230131,20200317,0.5742591619491577,"Disclosed herein are designer extracellular vesicles (EVs) functionalized with glutamate receptors (e.g., mGluR4 and mGluR8), which can selectively target CNS impaired regions that undergo excitatory toxicity",https://patents.google.com/patent/CN115666655,02/12/2025,NO
CN,120478653,A,Preparation method and application of GS-loaded mesenchymal stem cell exosome,"UNIV CHANGCHUN CHINESE MEDICINE, XINJINFANG JILIN MEDICAL TECH RESEARCH INSTITUTE CO LTD, 长春中医药大学,","JIN YE, CUI NING, LIU DA","The invention discloses a preparation method and application of a GS-loaded mesenchymal stem cell exosome, and belongs to the technical field of biology. In order to solve the problems of slow onset and long recovery period of a diabetic skin tissue defect healing method in the prior art, the invention provides a preparation method of a GS-loaded mesenchymal stem cell exosome, the yield of the MSCs exosome is induced to be greatly increased through high-frequency ultrasonic stimulation and a mic",20250815,20250721,0.55,"The invention discloses a preparation method and application of a GS-loaded mesenchymal stem cell exosome, and belongs to the technical field of biology. In order to solve the problems of slow onset and long recovery period of a diabetic skin tissue defect healing method in the prior art, the invention provides a preparation method of a GS-loaded mesenchymal stem cell exosome, the yield of the MSCs exosome is induced to be greatly increased through high-frequency ultrasonic stimulation and a microfluidic circulation technology, and the GS-loaded mesenchymal stem cell exosome is prepared. An original cell membrane structure is broken by using an acoustic fluid nano directional coupling technology, phospholipid bimolecules are driven to aggregate and self-assemble to form exosomes which are wrapped in GS, and effective drug delivery and synergistic tissue repair are realized; according to the method, nucleic acid, protein, saccharide, polypeptide and various small molecule compounds can be loaded in the exosome, and certain universality is achieved.",https://worldwide.espacenet.com/patent/search/family/CN120478653A,2025-12-30,NO
GB,2615671,A,Cannabis plant derived extracellular vesicles and therapeutic methods using the same,"UNIV FLORIDA [US], University of Florida Research Foundation, Incorporated","HASSAN AZARI [US], THOMAS D SCHMITTGEN [US], NASSER NASSIRI KOOPAEI [US]","Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety. New data using hemp derived EVs to treat cancers in the brain and to impact precursor cells in the brain and isolation of EVs are included. In addition, disclosed is an improvement on the efficacy of intra-nasal delivery and oral delivery when using EVs.",20230816,20200928,0.5494769215583801,"Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety",https://worldwide.espacenet.com/patent/search?q=pn%3DGB2615671,02/12/2025,NO
AU,2021350200,A1,CANNABIS PLANT DERIVED EXTRACELLULAR VESICLES AND THERAPEUTIC METHODS USING THE SAME,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED [US], UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED","AZARI HASSAN, SCHMITTGEN THOMAS, NASSIRI KOOPAEI NASSER","Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety. New data using hemp derived EVs to treat cancers in the brain and to impact precursor cells in the brain and isolation of EVs are included. In addition, disclosed is an improvement on the efficacy of intra-nasal delivery and oral delivery when using EVs.",20230608,20200928,0.5494769215583801,"Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety",https://worldwide.espacenet.com/patent/search?q=pn%3DAU2021350200,02/12/2025,NO
US,2024024227,A1,CANNABIS PLANT DERIVED EXTRACELLULAR VESICLES AND THERAPEUTIC METHODS USING THE SAME,"UNIV FLORIDA [US], UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED","AZARI HASSAN [US], SCHMITTGEN THOMAS D [US], NASSIRI KOOPAEI NASSER [US]","Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety. New data using hemp derived EVs to treat cancers in the brain and to impact precursor cells in the brain and isolation of EVs are included. In addition, disclosed is an improvement on the efficacy of intra-nasal delivery and oral delivery when using EVs.",20240125,20200928,0.5494769215583801,"Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety",https://patents.google.com/patent/US2024024227,02/12/2025,NO
WO,2022067223,A2,CANNABIS PLANT DERIVED EXTRACELLULAR VESICLES AND THERAPEUTIC METHODS USING THE SAME,"UNIV FLORIDA [US], UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED","AZARI HASSAN [US], SCHMITTGEN THOMAS [US], NASSIRI KOOPAEI NASSER [US]","Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety. New data using hemp derived EVs to treat cancers in the brain and to impact precursor cells in the brain and isolation of EVs are included. In addition, disclosed is an improvement on the efficacy of intra-nasal delivery and oral delivery when using EVs.",20220331,20200928,0.5494769215583801,"Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety",https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022067223,02/12/2025,NO
CA,3193856,A1,CANNABIS PLANT DERIVED EXTRACELLULAR VESICLES AND THERAPEUTIC METHODS USING THE SAME,"UNIV FLORIDA [US], UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED","AZARI HASSAN [US], SCHMITTGEN THOMAS D [US], NASSIRI KOOPAEI NASSER [US]","Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety. New data using hemp derived EVs to treat cancers in the brain and to impact precursor cells in the brain and isolation of EVs are included. In addition, disclosed is an improvement on the efficacy of intra-nasal delivery and oral delivery when using EVs.",20220331,20200928,0.5494769215583801,"Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety",https://worldwide.espacenet.com/patent/search?q=pn%3DCA3193856,02/12/2025,NO
WO,2025012776,A1,EXTRACELLULAR VESICLES FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS,"ARUNA BIO INC [US], ARUNA BIO, INC","STICE STEVEN L [US], BAKER EMILY [US], NARAYANAPPA AMRUTA [US]","Disclosed herein are methods of treating ALS in a subject by administering a therapeutically effective amount of a composition comprising EVs, e.g., derived from neural cells, e.g., neural progenitor cells, to the subject. The EVs can be administered distally or peripherally to the CNS, such that the EVs cross the blood brain barrier and exert their therapeutic function in the CNS. The methods can reduce inflammation (e.g., NLRP3 inflammatory pathway signaling), reduce disease activity or progression, and/or improve motor or neurological performance, signs or symptoms associated with ALS, or survival in the ALS subject as compared to a control ALS subject. The methods of inhibiting necroptosis in a cell by contacting the cell with a therapeutically effective amount of a composition comprising EVs are also provided.",20250116,20230707,0.5442964434623718,"Disclosed herein are methods of treating ALS in a subject by administering a therapeutically effective amount of a composition comprising EVs, e.g., derived from neural cells, e",https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025012776,02/12/2025,NO
CN,116600795,A,Cannabis plant-derived extracellular vesicles and methods of treatment using same,"UNIV FLORIDA, 佛罗里达大学研究基金会有限公司","AZARI HASSAN, SCHMIDTGEN TODD D, NASIRIKUPAY NASIRI","Disclosed are methods and compositions for delivering therapeutic molecules to CNS using plant extracellular vesicles (EVs) as vectors. Plant EV was demonstrated to be a more effective carrier than delivery by other methods. These vectors are useful in the treatment of central nervous system diseases, such as cancer, injury (e.g., TBI), degenerative disorders (e.g., Alzheimer's disease and aging), and cognitive disorders (e.g., PTSD, depression, and anxiety). Included are new data for treating cancer in the brain and affecting precursor cells in the brain and isolating EVs using cannabis derived EVs. In addition, improvements in intranasal and oral delivery effects when using the EV are disclosed.",20230815,20200928,0.525762677192688,"Disclosed are methods and compositions for delivering therapeutic molecules to CNS using plant extracellular vesicles (EVs) as vectors. Plant EV was demonstrated to be a more effective carrier than delivery by other methods. These vectors are useful in the treatment of central nervous system diseases, such as cancer, injury (e",https://patents.google.com/patent/CN116600795,02/12/2025,NO
WO,2023275617,A2,DIAGNOSTIC AND TREATMENT MONITORING BASED ON BLOOD-BRAIN BARRIER DISRUPTION,"INSIGHTEC LTD [IL], INSIGHTEC, LTD","ACHROL ACHAL [US], LEVY YOAV [IL], ACHROL, Achal,","The disclosure provides technologies that permit detection and/or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e.g., blood, serum, etc.). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials (e.g., brain-derived proteins, neuron-derived extracellular vesicles, and/or cell-free DNA) in readily-sampled systemic liquids.",20230105,20210701,0.523533821105957,"The disclosure provides technologies that permit detection and/or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e",https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023275617,02/12/2025,NO
US,2025263798,A1,DIAGNOSTIC AND TREATMENT MONITORING BASED ON BLOOD-BRAIN BARRIER DISRUPTION,"INSIGHTEC LTD [IL], INSIGHTEC LTD","ACHROL ACHAL SINGH [US], LEVY YOAV [IL], ACHROL, Achal Singh,","The disclosure provides technologies that permit detection and/or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e.g., blood, serum, etc.). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials (e.g., brain-derived proteins, neuron-derived extracellular vesicles, and/or cell-free DNA) in readily-sampled systemic liquids.",20250821,20210701,0.523533821105957,"The disclosure provides technologies that permit detection and/or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e",https://patents.google.com/patent/US2025263798,02/12/2025,NO
WO,2023212656,A1,BIOMATERIALS FOR IMPROVING BRAIN HEALING AFTER STROKE AND METHODS OF USING SAME,"UNIV DUKE [US], DUKE UNIVERSITY","SEGURA TATIANA [US], XIN SHANGJING [US], SEGURA, Tatiana,","Astrocytes are known to regulate the body responses to diseases and injuries in central nervous system (CNS). Embodiments of the instant disclosure relate to biomaterial for delivering extracellular vesicles derived from reactive cell populations for improving brain healing after injury. Also provided are methods of improving angiogenesis, axonogenesis, or inducing tissue repair using the disclosed biomaterials. Also provided are methods of making the biomaterials.",20231102,20220427,0.5224500298500061,"Astrocytes are known to regulate the body responses to diseases and injuries in central nervous system (CNS). Embodiments of the instant disclosure relate to biomaterial for delivering extracellular vesicles derived from reactive cell populations for improving brain healing after injury. Also provided are methods of improving angiogenesis, axonogenesis, or inducing tissue repair using the disclosed biomaterials",https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023212656,02/12/2025,NO
US,2023349906,A1,KINASES AS BIOMARKERS FOR NEURODEGENERATIVE CONDITIONS,"CHASE THERAPEUTICS CORP [US], Chase Therapeutics Corporation","CHASE THOMAS N [US], CLARENCE-SMITH KATHLEEN [US], Chase, Thomas N,","An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e.g., central nervous system (“CNS”)) derived microparticles, e.g., exosomes, from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) determining, in the isolated internal contents, set of biomarkers including: (1) at least one signaling kinase and, optionally, at least one oligomeric form of a neurodegenerative protein; or (2) a plurality of different signaling kinases.",20231102,20191231,0.5204287767410278,"An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e",https://patents.google.com/patent/US2023349906,02/12/2025,NO
PH,12022551608,A1,KINASES AS BIOMARKERS FOR NEURODEGENERATIVE CONDITIONS,"CHASE THERAPEUTICS CORP [US], CHASE THERAPEUTICS CORPORATION","CHASE THOMAS N [US], CLARENCE-SMITH KATHLEEN [US], CHASE, Thomas N,","An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e.g., central nervous system (""CNS"")) derived microparticles, e.g., exosomes, from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) determining, in the isolated internal contents, set of biomarkers including: (1) at least one signaling kinase and, optionally, at least one oligomeric form of a neurodegenerative protein; or (2) a plurality of different signaling kinases.",20231016,20191231,0.5169281959533691,"An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e",https://worldwide.espacenet.com/patent/search?q=pn%3DPH12022551608,02/12/2025,NO
AU,2020416213,A1,Kinases as biomarkers for neurodegenerative conditions,"CHASE THERAPEUTICS CORP [US], CHASE THERAPEUTICS CORPORATION","CHASE THOMAS N, CLARENCE-SMITH KATHLEEN, CHASE, Thomas N,","An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e.g., central nervous system (""CNS"")) derived microparticles, e.g., exosomes, from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) determining, in the isolated internal contents, set of biomarkers including: (1) at least one signaling kinase and, optionally, at least one oligomeric form of a neurodegenerative protein; or (2) a plurality of different signaling kinases.",20220721,20191231,0.5169281959533691,"An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e",https://worldwide.espacenet.com/patent/search?q=pn%3DAU2020416213,02/12/2025,NO
CN,115884788,A,Kinases as biomarkers for neurodegenerative conditions,"CHASE THERAPEUTICS CORP, 才思治疗公司","THOMAS N CHASE, CLARENCE-SMITH KATHLEEN, 托马斯·N·蔡斯,","Assays using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins may comprise: a) providing a biological sample, such as a blood sample, from a subject; b) enriching neuronal (e.g., central nervous system (""CNS"")) derived microparticles, e.g., exosomes, from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) determining a set of biomarkers in the isolated internal content, the set of biomarkers comprising: (1) at least one signaling kinase and optionally at least one oligomeric form of a neurodegenerative protein; or (2) more than one different signaling kinase.",20230331,20191231,0.513897180557251,"Assays using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins may comprise: a) providing a biological sample, such as a blood sample, from a subject; b) enriching neuronal (e.g., central nervous system (""CNS"")) derived microparticles, e",https://patents.google.com/patent/CN115884788,02/12/2025,NO
CN,117957446,A,Diagnostic and therapeutic monitoring based on blood brain barrier disruption,"INSIGHTEC LTD, 医视特有限公司","AKRO AHMED S, LEVY YOAV, A·S·阿克罗,","The present disclosure provides techniques that allow for the detection and/or characterization of brain biomarkers (e.g., disease-related biomarkers) in non-CNS samples, including by liquid biopsy (e.g., blood, serum, etc. The present disclosure demonstrates, among other things, that ultrasonic opening of the blood brain barrier can achieve a detectable increase in brain-derived substances (e.g., brain-derived proteins, neuronal-derived extracellular vesicles, and/or cell-free DNA) in a systemic fluid that is easy to sample.",20240430,20210701,0.4974712133407593,"The present disclosure provides techniques that allow for the detection and/or characterization of brain biomarkers (e.g., disease-related biomarkers) in non-CNS samples, including by liquid biopsy (e",https://patents.google.com/patent/CN117957446,02/12/2025,NO
MX,2022008111,A,KINASES AS BIOMARKERS FOR NEURODEGENERATIVE CONDITIONS.,"CHASE THERAPEUTICS CORP [US], CHASE THERAPEUTICS CORPORATION","CHASE THOMAS N [US], CLARENCE-SMITH KATHLEEN, CHASE Thomas N,","An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e.g., central nervous system (""CNS"")) derived microparticles, e.g., exosomes, from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) determining, in the isolated internal contents, set of biomarkers including: (1) at least one signaling kinase and, optionally, at least one oligomeric form of a neurodegenerative protein; or (2) a plurality of different signaling kinases.",20230222,20191231,0.4878576695919037,"An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e",https://worldwide.espacenet.com/patent/search?q=pn%3DMX2022008111,02/12/2025,NO
US,2022395538,A1,FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE,"FIGENE LLC [US], FIGENE, LLC","O'HEERON PETE [US], ICHIM THOMAS [US], O'HEERON, Pete,","In some aspects, disclosed herein are methods and compositions for treatment or prevention of CNS disorders (e.g., stroke) using fibroblasts or derivatives thereof. Disclosed herein are fibroblasts and derivatives thereof capable of inducing neuroregeneration and/or reducing neuroinflammation in a subject. Aspects comprise methods and compositions for stimulating neural progenitor cell proliferation. In some cases, methods comprise providing fibroblasts and stem cells (e.g., hematopoietic stem cells) to an individual to treat or prevent a stroke. Embodiments are directed to exosomes or other microvesicles (e.g., apoptotic bodies) derived from fibroblasts for use in treating or preventing stroke in an individual. In some aspects, disclosed are means, methods, and compositions of matter useful for treatment of cerebral hemorrhage through administration of fibroblasts, modification of fibroblasts, and/or derivatives of fibroblasts such as exosomes, microvesicles, and/or apoptotic bodies. In one embodiment, fibroblasts, modified fibroblasts, and/or derivatives thereof are administered for induction of neuroprotective properties and/or stimulation of neuroregeneration.",20221215,20191117,0.4379005432128906,"In some aspects, disclosed herein are methods and compositions for treatment or prevention of CNS disorders (e.g., stroke) using fibroblasts or derivatives thereof",https://patents.google.com/patent/US2022395538,02/12/2025,NO
WO,2023223312,A1,ANTI-PTEN RNA INTERFERENCE OLIGONUCLEOTIDES AND USES THEREOF,"NUREXONE BIOLOGIC LTD [IL], NUREXONE BIOLOGIC LTD","PERETS NISIM [IL], AHARONOV LYORA [IL], SHALTIEL LIOR [IL]","The present invention provides RNA interference (RNAi) oligonucleotides inhibiting expression of Phosphatase and tensin homolog (PTEN), extracellular vesicles comprising the RNAi oligonucleotides, pharmaceutical compositions including the RNAi oligonucleotides or said extracellular vesicles and their use in the treatment of neurological and CNS disorders and, more particularly to their use for the treatment of spinal cord injuries.",20231123,20220515,0.386127233505249,"The present invention provides RNA interference (RNAi) oligonucleotides inhibiting expression of Phosphatase and tensin homolog (PTEN), extracellular vesicles comprising the RNAi oligonucleotides, pharmaceutical compositions including the RNAi oligonucleotides or said extracellular vesicles and their use in the treatment of neurological and CNS disorders and, more particularly to their use for the treatment of spinal cord injuries.",https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023223312,02/12/2025,NO
US,2025136992,A1,ANTI-PTEN RNA INTERFERENCE OLIGONUCLEOTIDES AND USES THEREOF,"NUREXONE BIOLOGIC LTD [IL], NUREXONE BIOLOGIC LTD","PERETS NISIM [IL], AHARONOV LYORA [IL], SHALTIEL LIOR [IL]","The present invention provides RNA interference (RNAi) oligonucleotides inhibiting expression of Phosphatase and tensin homolog (PTEN), extracellular vesicles comprising the RNAi oligonucleotides, pharmaceutical compositions including the RNAi oligonucleotides or said extracellular vesicles and their use in the treatment of neurological and CNS disorders and, more particularly to their use for the treatment of spinal cord injuries.",20250501,20220515,0.386127233505249,"The present invention provides RNA interference (RNAi) oligonucleotides inhibiting expression of Phosphatase and tensin homolog (PTEN), extracellular vesicles comprising the RNAi oligonucleotides, pharmaceutical compositions including the RNAi oligonucleotides or said extracellular vesicles and their use in the treatment of neurological and CNS disorders and, more particularly to their use for the treatment of spinal cord injuries.",https://patents.google.com/patent/US2025136992,02/12/2025,NO
AU,2023270605,A1,ANTI-PTEN RNA INTERFERENCE OLIGONUCLEOTIDES AND USES THEREOF,"NUREXONE BIOLOGIC LTD [IL], NUREXONE BIOLOGIC LTD","PERETS NISIM, AHARONOV LYORA, SHALTIEL LIOR","The present invention provides RNA interference (RNAi) oligonucleotides inhibiting expression of Phosphatase and tensin homolog (PTEN), extracellular vesicles comprising the RNAi oligonucleotides, pharmaceutical compositions including the RNAi oligonucleotides or said extracellular vesicles and their use in the treatment of neurological and CNS disorders and, more particularly to their use for the treatment of spinal cord injuries.",20241205,20220515,0.386127233505249,"The present invention provides RNA interference (RNAi) oligonucleotides inhibiting expression of Phosphatase and tensin homolog (PTEN), extracellular vesicles comprising the RNAi oligonucleotides, pharmaceutical compositions including the RNAi oligonucleotides or said extracellular vesicles and their use in the treatment of neurological and CNS disorders and, more particularly to their use for the treatment of spinal cord injuries.",https://worldwide.espacenet.com/patent/search?q=pn%3DAU2023270605,02/12/2025,NO
CN,119183475,A,Anti-PTEN RNA interference oligonucleotides and uses thereof,"NOAXOON BIOPHARMACEUTICALS LLC, 诺艾克叟恩生物制药有限公司","PERETZ NORBERT, AHARONOV LIOR, SALTIER LAURENT","The present invention provides RNA interference (RNAi) oligonucleotides that inhibit the expression of phosphatase and tensin homolog (PTEN), extracellular vesicles comprising said RNAi oligonucleotides, pharmaceutical compositions comprising said RNAi oligonucleotides or said extracellular vesicles, and uses thereof in the treatment of neurological and CNS disorders, and more particularly to their use for the treatment of spinal cord injury.",20241224,20220515,0.3858356475830078,"The present invention provides RNA interference (RNAi) oligonucleotides that inhibit the expression of phosphatase and tensin homolog (PTEN), extracellular vesicles comprising said RNAi oligonucleotides, pharmaceutical compositions comprising said RNAi oligonucleotides or said extracellular vesicles, and uses thereof in the treatment of neurological and CNS disorders, and more particularly to their use for the treatment of spinal cord injury.",https://patents.google.com/patent/CN119183475,02/12/2025,NO
JP,2024063160,A,ALPHA-SYNUCLEIN ASSAYS,"CHASE THERAPEUTICS CORP, チェイス  セラピューティクス  コーポレイション","THOMAS N CHASE, KATHLEEN CLARENCE-SMITH, チェイス  トーマス  エヌ．,","To provide an assay for alpha synuclein and its various forms.SOLUTION: An assay for alpha synuclein and its various forms includes: (a) providing a blood sample from a subject; (b) isolating central nervous system (""CNS"")-derived exosomes from the blood sample; (c) removing proteins from the surface of the isolated exosomes to generate scrambled exosomes; (d) isolating the internal contents of the scrubbed exosomes; (e) determining the oligomeric α-synuclein protein in the isolated internal content; (f) separating oligomeric α-synuclein species into a plurality of fractions; and (g) determining quantitative measurements of one or more isolated oligomeric α-synuclein species and, optionally, one or more species selected from monomeric α-synuclein, tau-synuclein copolymers, amyloid β-synuclein copolymers and tau-amyloid β-synuclein copolymers.SELECTED DRAWING: Figure 1",20240510,20190430,0.3750349283218384,"To provide an assay for alpha synuclein and its various forms.SOLUTION: An assay for alpha synuclein and its various forms includes: (a) providing a blood sample from a subject; (b) isolating central nervous system (""CNS"")-derived exosomes from the blood sample; (c) removing proteins from the surface of the isolated exosomes to generate scrambled exosomes; (d) isolating the internal contents of the scrubbed exosomes; (e) determining the oligomeric α-synuclein protein in the isolated internal con",https://worldwide.espacenet.com/patent/search?q=pn%3DJP2024063160,02/12/2025,NO
JP,2024112950,A,METHODS FOR DEVELOPING PHARMACEUTICALS FOR TREATING NEURODEGENERATIVE CONDITIONS,"CHASE THERAPEUTICS CORP, チェイス  セラピューティクス  コーポレイション","THOMAS N CHASE, KATHLEEN CLARENCE-SMITH, チェイス  トーマス  エヌ．,","To provide methods of developing pharmaceuticals for treatment of neurodegenerative conditions, such as synucleopathic conditions, amyloidopathic conditions, tauopathic conditions, and Huntington's disease.SOLUTION: The methods involve using a biomarker to determine the effect of a candidate pharmaceutical on the condition. The biomarker profile includes quantitative measures of each of one or a plurality of neurodegenerative protein forms, wherein the neurodegenerative proteins are, for example, alpha-synuclein and, amyloid beta, tau or huntingtin. Biomarker profiles include one or more oligomeric forms and, optionally, one or more monomeric forms of the neurodegenerative protein. Neurodegenerative proteins can be quantified from, for example, CNS-derived exosomes from the blood of a subject.SELECTED DRAWING: Figure 4",20240821,20171219,0.3642773926258087,"To provide methods of developing pharmaceuticals for treatment of neurodegenerative conditions, such as synucleopathic conditions, amyloidopathic conditions, tauopathic conditions, and Huntington's disease.SOLUTION: The methods involve using a biomarker to determine the effect of a candidate pharmaceutical on the condition. The biomarker profile includes quantitative measures of each of one or a plurality of neurodegenerative protein forms, wherein the neurodegenerative proteins are, for example",https://worldwide.espacenet.com/patent/search?q=pn%3DJP2024112950,02/12/2025,NO
CN,114341343,A,Alpha-synuclein assay,"TANLII TREAT COMPANY, 才思治疗公司","THOMAS N CHASE, CLARENCE-SMITH KATHLEEN, 托马斯·N·蔡斯,","A method for assaying alpha synuclein and forms thereof, comprising: a) providing a blood sample from a subject; b) isolating a central nervous system (""CNS"")-derived exosome from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) separating the internal contents of the scrubbed exosome; e) determining a quantitative measurement of oligomeric alpha-synuclein and optionally one or more protein forms selected from the group consisting of monomeric alpha-synuclein, phosphorylated alpha-synuclein, monomeric tau, oligomeric tau, phosphorylated tau, amyloid beta (""a-beta"") 1-40, amyloid beta 1-42 and oligomeric amyloid beta in the isolated internal content; f) separating the species of oligomeric alpha-synuclein into more than one fraction; g) determining a quantitative measurement of one or more isolated oligomeric alpha-synuclein species and optionally each of one or more species selected from the group consisting of monomeric alpha-synuclein, tau-synuclein copolymers, oligomeric alpha-synuclein copolymers, oligomeric alpha-synuclein copolymers, oligomeric alpha-synuclein copolymers, oligomeric alpha-synuclein copolymers, oligomeric alpha-synuclein copolymers, oligomeric alpha-synuclein copolymers, and oligomeric alpha-synuclein copolymers. The invention relates to an amyloid beta-synuclein copolymer and a tau-amyloid beta-synuclein copolymer.",20220412,20190430,0.3340760171413421,"A method for assaying alpha synuclein and forms thereof, comprising: a) providing a blood sample from a subject; b) isolating a central nervous system (""CNS"")-derived exosome from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) separating the internal contents of the scrubbed exosome; e) determining a quantitative measurement of oligomeric alpha-synuclein and optionally one or more protein forms selected from the group consisting",https://patents.google.com/patent/CN114341343,02/12/2025,NO
US,2022214360,A1,ALPHA-SYNUCLEIN ASSAYS,"CHASE THERAPEUTICS CORP [US], Chase Therapeutics Corporation","CHASE THOMAS N [US], CLARENCE-SMITH KATHLEEN [US], CHASE, Thomas N,","An assay for alpha synuclein and its various forms includes: a) providing a blood sample from a subject; b) isolating central nervous system (“CNS”) derived exosomes from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) isolating the internal contents of the scrubbed exosomes; e) determining, in the isolated internal contents, a quantitative measure of oligomeric α-synuclein protein and, optionally, one or a plurality of protein forms selected from: monomeric α-synuclein, phosphorylated α-synuclein, monomeric tau, oligomeric tau, phosphorylated tau, amyloid beta (“a-beta”) 1-40, amyloid beta 1-42, and oligomeric amyloid beta; f) separating species of oligomeric α-synuclein into a plurality of fractions; g) determining a quantitative measure of each of one or a plurality of the separated oligomeric α-synuclein species and, optionally, one or a plurality of species selected from: monomeric α-synuclein, tau-synuclein co-polymers, amyloid beta-synuclein co-polymers and tau-amyloid beta-synuclein co-polymers.",20220707,20190430,0.3227031230926513,"An assay for alpha synuclein and its various forms includes: a) providing a blood sample from a subject; b) isolating central nervous system (“CNS”) derived exosomes from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) isolating the internal contents of the scrubbed exosomes; e) determining, in the isolated internal contents, a quantitative measure of oligomeric α-synuclein protein and, optionally, one or a plurality of protein fo",https://patents.google.com/patent/US2022214360,02/12/2025,NO
EP,4273882,A2,METHOD FOR ASSESSING A SYNUCLEINOPATHY,"CHASE THERAPEUTICS CORP [US], Chase Therapeutics Corporation","CHASE THOMAS N [US], CLARENCE-SMITH KATHLEEN [US], Chase, Thomas N,","Provided herein are methods of developing pharmaceuticals for treatment of neurodegenerative conditions, such as synucleopathic conditions, amyloidopathic conditions, tauopathic conditions, and Huntington's disease. The methods involve using a biomarker to determine the effect of a candidate pharmaceutical on the condition. The biomarker profile includes quantitative measures of each of one or a plurality of neurodegenerative protein forms, wherein the neurodegenerative proteins are, e.g., alpha-synuclein and, amyloid beta, tau or huntingtin. Biomarker profiles include one or more oligomeric forms and, optionally, one or more monomeric forms of the neurodegenerative protein. Neurodegenerative proteins can be quantified from, e.g., CNS-derived exosomes from the blood of a subject.",20231108,20171219,0.2677425146102905,"Provided herein are methods of developing pharmaceuticals for treatment of neurodegenerative conditions, such as synucleopathic conditions, amyloidopathic conditions, tauopathic conditions, and Huntington's disease. The methods involve using a biomarker to determine the effect of a candidate pharmaceutical on the condition. The biomarker profile includes quantitative measures of each of one or a plurality of neurodegenerative protein forms, wherein the neurodegenerative proteins are, e",https://worldwide.espacenet.com/patent/search?q=pn%3DEP4273882,02/12/2025,NO
